Fig. 5

Administration of PEG-ChAT during dark cycle (active cycle) decreases blood pressure. A mean MAP in light cycle following a dark cycle administration of ChAT. ChAT was administered in the middle of the dark cycle (6 h), and MAP is averaged 6–18 h post-ChAT administration. Data are represented as individual mouse points with mean ± SEM. n = 8–15. ns not significant, one-way ANOVA with Dunnett’s multiple comparison test. B MAP in 24 h post-ChAT administration in dark cycle. Gray background indicates dark cycle. Data are averaged every hour and represented with lines as group mean ± SEM. n = 8–15. ****p < 0.0001, vehicle vs. 0.1 mg/kg ChAT, ^####p < 0.0001, vehicle vs. 1 mg/kg ChAT, two-way ANOVA with Tukey’s multiple comparison test. C mean MAP in light cycle following a dark cycle administration of PEG-ChAT. PEG-ChAT was administered in the middle of the dark cycle (6 h), and MAP is averaged 6–18 h post-ChAT administration. Data are represented as individual mouse points with mean ± SEM. n = 12–21. **p < 0.01, ****p < 0.0001, one-way ANOVA with Dunnett’s multiple comparison test. D MAP in 24 h post-PEG-ChAT administration in dark cycle. Gray background indicates dark cycle. While there is no initial transient BP decrease, MAP is decreased during the next light cycle phase. Data are averaged every hour and represented with lines as group mean ± SEM. n = 12–21. ****p < 0.0001, vehicle vs. 0.1 mg/kg or 1 mg/kg PEG-ChAT, two-way ANOVA with Tukey’s multiple comparison test